Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: A multicenter prospective study of 2302 patients in China
机构：[1]Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Beijing, China[2]Department of Hematology, First Affiliated Hospital of Zhongshan University, Guangzhou, China[3]Department of Hematology, Wuhan Union Hospital, Wuhan, China华中科技大学同济医学院附属协和医院[4]Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China[5]Department of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[6]Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China[7]Department of Hematology, Peking Union Medical College Hospital, Beijing, China[8]Department of Hematology, Xiangya Hospital of Central-South University, Changsha, China[9]Department of Hematology, Shengjing Hospital, China Medical University, Shenyang, China中国医科大学附属盛京医院[10]Department of Hematology, West China Hospital of Sichuan University, Chengdu, China四川大学华西医院[11]Department of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China[12]Department of Hematology, Shanghai First People's Hospital, Shanghai, China[13]Department of Hematology, Henan Province People's Hospital, Zhengzhou, China[14]Department of Hematology, First Affiliated Hospital, China Medical University, Shenyang, China[15]Department of Hematology, Qilu Hospital of Shandong University, Jinan, China[16]Department of Hematology, Guangdong Provincial People′s Hospital, Guangzhou, China[17]Department of Hematology, Shandong Provincial Hospital of Shandong University, Jinan, China[18]Department of Hematology, First Affiliated Hospital of Jilin University, Changchun, China[19]Department of Hematology, First Affiliated Hospital, Guangxi Medical University, Nanning, China[20]Department of Hematology, First Clinical College of Harbin Medical University, Harbin, China[21]Department of Hematology, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, China[22]Department of Hematology, First Affiliated Hospital of Dalian Medical University, Dalian, China大连医科大学附属第一医院[23]Harbin Institute of Hematology and Oncology, Harbin, China[24]Department of Hematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China[25]Department of Hematology, Second Xiangya Hospital of Central-South University, Changsha, China[26]Department of Hematology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China[27]Department of Hematology, Tangdu Hospital, Fourth Military Medical University, Xian, China[28]Department of Hematology, Second Hospital of Lanzhou University, Lanzhou, China[29]Department of Hematology, Xijing Hospital Affiliated to the Fourth Military Medical University, Xian, China[30]Department of Hematology, Lanzhou General Hospital of Lanzhou Command, Lanzhou, China[31]Department of Hematology, People′s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
In an attempt to establish the advantages of fluorescence in situ hybridization (FISH) studies over conventional cytogenetic (CC) analysis, a total of 2302 de novo MDS patients from 31 Chinese institutions were prospectively selected in the present study for both CC and standardized FISH analysis for +8, -717q-, -515q-, 20q- and-Y chromosomal abnormalities. CC analysis was successful in 94.0% of the patients; of these patients, 35.9% of the cases were abnormal. FISH analysis was successful in all 2302 patients and detected at least one type of common cytogenetic abnormality in 42.7% of the cases. The incidences of +8, -717q-, -515q-, 20q- and-Y chromosomal abnormalities by FISH were 4.1% to 8.7% higher than those by CC. FISH identified abnormalities in 23.6% of the patients exhibiting normal CC results and revealed that 20.7% of the patients with adequate normal metaphases (>= 20) had abnormal clones. FISH identified cytogenetic abnormalities in 50.4% of the patients with failed CC analysis. In summary, our multicenter studies emphasised and confirmed the importance of applying standardized FISH testing based on an appropriate panel of probes to detect common cytogenetic abnormalities in Chinese de novo MDS patients, particularly those with normal or failed CC results. (C) 2015 Published by Elsevier Ltd.
基金：
Chinese Medical Association onclinical application of molecular biology technique (CAMB042010).
第一作者机构：[1]Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Beijing, China
通讯作者：
推荐引用方式(GB/T 7714)：
Lai Yue-Yun,Huang Xiao-Jun,Li Juan,et al.Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: A multicenter prospective study of 2302 patients in China[J].LEUKEMIA RESEARCH.2015,39(5):530-535.doi:10.1016/j.leukres.2015.02.005.
APA：
Lai, Yue-Yun,Huang, Xiao-Jun,Li, Juan,Zou, Ping,Xu, Ze-Feng...&Lin, Jin-Ying.(2015).Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: A multicenter prospective study of 2302 patients in China.LEUKEMIA RESEARCH,39,(5)
MLA：
Lai, Yue-Yun,et al."Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: A multicenter prospective study of 2302 patients in China".LEUKEMIA RESEARCH 39..5(2015):530-535
